PRAX vs. RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, KYMR, and MOR
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
Praxis Precision Medicines vs. Its Competitors
Praxis Precision Medicines (NASDAQ:PRAX) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Praxis Precision Medicines has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Praxis Precision Medicines presently has a consensus target price of $92.11, suggesting a potential upside of 97.32%. Avidity Biosciences has a consensus target price of $65.59, suggesting a potential upside of 127.74%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Praxis Precision Medicines.
Praxis Precision Medicines has a net margin of -2,137.48% compared to Avidity Biosciences' net margin of -4,136.00%. Avidity Biosciences' return on equity of -26.96% beat Praxis Precision Medicines' return on equity.
In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 2 articles in the media. Avidity Biosciences' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of 0.42 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Praxis Precision Medicines has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Summary
Avidity Biosciences beats Praxis Precision Medicines on 11 of the 16 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:PRAX) was last updated on 7/8/2025 by MarketBeat.com Staff
Free PRAX Stock Alerts